Stereoselective synthesis of the two major metabolites of spironolactone, 3α- and 3β-hydroxy-7α-methylthio-17α-pregn-4-ene-21,17-carbolactoneGUO LI; YAN ZHANG.Steroids. 2007, Vol 72, Num 6-7, pp 569-572, issn 0039-128X, 4 p.Article

Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolitesGARDINER, P; SCHRODE, K; QUINLAN, D et al.Journal of clinical pharmacology. 1989, Vol 29, Num 4, pp 342-347, issn 0091-2700Article

Spironolactone in the treatment of premenstrual tension : a double-blind study of spironolactone versus bendroflumethiazide and placeboASLAKSEN, K; FALK, V.Current therapeutic research. 1991, Vol 49, Num 1, pp 120-130, issn 0011-393X, 11 p.Article

Protective effect of spironolactone on endothelial cell apoptosisWILLIAMS, Tracy A; VERHOVEZ, Andrea; MILAN, Alberto et al.Endocrinology (Philadelphia). 2006, Vol 147, Num 5, pp 2496-2505, issn 0013-7227, 10 p.Article

Pharmacokinetics and metabolism of [¹⁴C]eplerenone after oral administration to humansCOOK, Chyung S; BERRY, Loren M; BIBLE, Roy H et al.Drug metabolism and disposition. 2003, Vol 31, Num 11, pp 1448-1455, issn 0090-9556, 8 p.Article

Mineralocorticoid Receptor Blocker Eplerenone Reduces Pain Behaviors In Vivo and Decreases Excitability in Small-diameter Sensory Neurons from Local Inflamed Dorsal Root Ganglia In VitroFEI DONG; WENRUI XIE; STRONG, Judith A et al.Anesthesiology (Philadelphia). 2012, Vol 117, Num 5, pp 1102-1112, issn 0003-3022, 11 p.Article

Preparation and characterization of spironolactone-loaded nanocapsules for paediatric useLIMAYEM BLOUZA, I; CHARCOSSET, C; SFAR, S et al.International journal of pharmaceutics. 2006, Vol 325, Num 1-2, pp 124-131, issn 0378-5173, 8 p.Article

The Effect of Aldosterone Antagonists for Ventricular Arrhythmia: A Meta-AnalysisJIAFU WEI; JUAN NI; DEJIA HUANG et al.Clinical cardiology (Mahwah, NJ). 2010, Vol 33, Num 9, pp 572-577, issn 0160-9289, 6 p.Article

Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 YearsBECKER, Matthijs L; VISSER, Loes E; VAN GELDER, Teun et al.Drugs & aging. 2008, Vol 25, Num 2, pp 145-152, issn 1170-229X, 8 p.Article

Column liquid chromatography of the novel aldosterone antagonist, mespirenone, and its active metabolite in plasmaHILDEBRAND, M; SCHÜTT, A.Journal of chromatography. 1987, Vol 414, Num 1, pp 217-222, issn 0021-9673Article

Isolation and identification of novel impurities in spironolactoneHUA CHEN; WANG, You-Fu; YANG, Zhong-Duo et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 40, Num 5, pp 1263-1267, issn 0731-7085, 5 p.Article

Ouabain-inhibiting activity of aldosterone antagonistsSEMPLICINI, A; SERENA, L; VALLE, R et al.Steroids. 1995, Vol 60, Num 1, pp 110-113, issn 0039-128XConference Paper

Long-Term Effects of Spironolactone in Peritoneal Dialysis PatientsITO, Yasuhiko; MIZUNO, Masashi; YUZAWA, Yukio et al.Journal of the American Society of Nephrology. 2014, Vol 25, Num 5, pp 1094-1102, issn 1046-6673, 9 p.Article

Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat HospitalizationsROGERS, Jennifer K; MCMURRAY, John J. V; POCOCK, Stuart J et al.Circulation (New York, N.Y.). 2012, Vol 126, Num 19, pp 2317-2323, issn 0009-7322, 7 p.Article

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertensionSATO, A; FUKUDA, S.Journal of human hypertension. 2010, Vol 24, Num 6, pp 387-394, issn 0950-9240, 8 p.Article

The effect of spironolactone on sweat and urinary sodium excretion during exercise in humansLEE, Nanette V. L; MILLER, Paul W; BUONO, Michael J et al.Clinical physiology and functional imaging (Print). 2010, Vol 30, Num 1, pp 13-16, issn 1475-0961, 4 p.Article

A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutismKELESTIMUR, Fahrettin; EVEREST, Hatice; ÜNLÜHIZARCI, Kürsad et al.European journal of endocrinology. 2004, Vol 150, Num 3, pp 351-354, issn 0804-4643, 4 p.Article

Influence of spironolactone treatment on gentamicin-induced nephrotoxicity in ratsALI, Badreldin H; AL-QARAWI, Ali A; MAHMOUD, Osama M et al.Basic & clinical pharmacology & toxicology (Print). 2004, Vol 95, Num 1, pp 20-23, issn 1742-7835, 4 p.Article

La renaissance de l'aldostérone et de ses antagonistes : Hypertension = The revival of aldosterone and its antagonistsBURNIE, M.Médecine et hygiène. 2002, Vol 60, Num 2397, pp 1251-1254, issn 0025-6749Article

Spironolactone-induced hepatitisTHAI, Keng-Ee; SINCLAIR, Rodney D.Australasian journal of dermatology. 2001, Vol 42, Num 3, pp 180-182, issn 0004-8380Article

Antagonistes de l'aldostérone: nouvelles cibles pharmacologiques : Actualités sur le Système Rénine-Angiotensine-Aldostérone = Antimineralocorticoids: pharmacological prospectsDE JONG, W; GRIMA, M; BARTHELMEBS, M et al.Thérapie (Paris). 1998, Vol 53, Num 3, pp 237-243, issn 0040-5957Article

Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are presentDE MENDONCA, M; GRICHOIS, M.-L; PERNOLLET, M.-G et al.Journal of cardiovascular pharmacology. 1988, Vol 11, Num 1, pp 75-83, issn 0160-2446Article

Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canreonateCOOK, C. S; HAUSWALD, C. L; OPPERMANN, J. A et al.Archives of toxicology. 1988, Vol 61, Num 3, pp 201-212, issn 0340-5761Article

A diastereoselective synthesis of 7α-nitromethyl steroid derivative and its use for an efficient synthesis of eplerenoneBIN ZHANG; HONGLI CHEN; HUANYU TANG et al.Steroids. 2012, Vol 77, Num 11, pp 1086-1091, issn 0039-128X, 6 p.Article

Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose DietWADA, Tsutomu; KENMOCHI, Hiroki; MIYASHITA, Yusuke et al.Endocrinology (Philadelphia). 2010, Vol 151, Num 5, pp 2040-2049, issn 0013-7227, 10 p.Article